Analysts’ Viewpoint
Increase in prevalence of chronic diseases, including heart diseases, stroke, diabetes, hypertension, and cancer, is projected to augment diuretic drugs market value in the near future. Rise in demand for diuretic drugs among athletes is also fueling market progress. Growth in awareness about benefits of diuretic drugs among those suffering from various chronic disorders is expected to boost the global diuretic drugs market scope during the forecast period.
Rise in aging population, increase in adoption of unhealthy lifestyle, and surge in rate of obesity are also driving market dynamics. Growth in adoption of diuretic drugs in emerging economies is creating lucrative opportunities for market players. Companies in the global market are introducing new medications to treat several chronic diseases.
Diuretics, sometimes known as water pills or fluid pills, are medications that increase urine production. The body uses urination to eliminate extra salt and water. This helps reduce blood pressure in addition to relieving symptoms such as ankle swelling.
Carbonic anhydrase inhibitors, loop diuretics, potassium-sparing diuretics, and thiazide diuretics are some of the common types of diuretic drugs. Thiazides are the most common diuretics for hypertension. Heart failure is often treated with loop diuretics. These medications include bumetanide, torsemide (demadex), and furosemide (lasix).
Potassium is an essential nutrient that lowers the amount of fluid in the body. Potassium-sparing diuretics may be administered to people who are at the risk of low potassium levels, including those who take other drugs that deplete potassium.
Some athletes use diuretics to lose weight quickly, especially in sports that emphasize weight classes or body appearances, such as wrestling, boxing, and bodybuilding. Diuretics are substances that increase the amount of urine produced by the body, leading to a rapid loss of water weight. Athletes may use diuretics to achieve a certain weight class or enhance their muscle definition by reducing water retention and bloating.
However, the usage of diuretics for weight loss is considered a deceitful practice in sports. It is banned by most athletic organizations. Diuretics are classified as masking agents; they can be used to hide the presence of other banned substances in the body.
Diuretics are commonly used in the treatment of chronic diseases such as heart failure, kidney disease, and liver cirrhosis. The usage of diuretics in chronic diseases is aimed at managing symptoms and complications associated with these conditions, such as fluid overload, edema, and high blood pressure.
In patients with heart failure, diuretics are often prescribed to reduce fluid buildup in the lungs and other tissues, which can cause shortness of breath, coughing, and fatigue. Diuretics can help reduce the workload on the heart and improve cardiac function, thus leading to better overall health outcomes.
In patients with kidney diseases, diuretics can help reduce fluid overload and manage edema, a common complication of chronic kidney disease. However, the usage of diuretics in kidney disease patients requires close monitoring of the kidney function, electrolyte levels, and blood pressure in order to avoid further damage to the kidneys and other complications.
In patients with cirrhosis of the liver, diuretics can help reduce ascites, a condition where fluid builds up in the abdomen, thus causing discomfort and increased risk of infection.
Diuretics can be effective in managing symptoms and complications of chronic diseases. However, they are not without risks. Common side-effects of diuretics include dehydration, electrolyte imbalances, and low blood pressure, which can be particularly dangerous in patients with chronic diseases.
In terms of drug class, the global market has been classified into carbonic anhydrase inhibitors, loop diuretics, miscellaneous diuretics, potassium-sparing diuretics, and thiazide diuretics. The thiazide diuretics segment accounted for major share in 2022.
Thiazide diuretics are less effective at causing diuresis and natriuresis than loop diuretics drugs, as the sodium chloride transporter in the distal tubule typically reabsorbs just around 5.0% of filtered salt. Nevertheless, they are potent enough to address a variety of therapeutic requirements for a diuretic.
Based on route of administration, the global industry has been bifurcated into oral and parenteral. The oral segment accounted for major share in 2022. The segment is estimated to maintain its share throughout the forecast period, as per the latest diuretic drugs market forecast analysis.
According to the latest diuretic drugs market trends, oral administration of diuretic drugs is a commonly used method. It is more convenient than parenteral administration. It is the most prescribed route of drug administration, as it is easy to administer and provides a predictable absorption of the medication.
Based on indication, the global market has been divided into hypertension, edema, heart failure, kidney stone, and others. According to the latest diuretic drugs market analysis, the hypertension segment accounted for major share of the global market in 2022. The segment is likely to dominate the global landscape in the next few years.
Diuretics are one of the first-line treatments for hypertension, and are commonly prescribed in combination with other antihypertensive medications.
In terms of distribution channel, the global market has been segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The retail pharmacies segment accounted for the largest share in 2022. It is expected to lead the market in the near future. Increase in availability of prescribed oral drugs in retail pharmacies is a key factor augmenting the segment.
North America constituted major diuretic drugs market share in 2022. The region is anticipated to maintain its dominance throughout the forecast period. The diuretic drugs market size is projected to increase in North America during the forecast period, owing to the rise in prevalence of chronic diseases in the region.
According to the Centers for Disease Control and Prevention, every six in 10 adults are suffering from chronic diseases in North America. Chronic diseases such as diabetes, cancer, and heart diseases are considered to be the major causes of mortality and disability in the U.S. Increase in healthcare expenditure is also fueling market statistics in the region.
The market in Asia Pacific is likely to grow at a rapid pace from 2023 to 2031. According to the World Health Organization (WHO), 41 million people die from noncommunicable diseases (NCDs) every year, accounting for 74.0% of all deaths worldwide. Rise in incidence of NCDs is fueling the demand for diuretic drugs in the region.
As per the latest diuretic drugs market research report, the global industry is fragmented, with the presence of large number of local as well as international players. Expansion of product portfolio and mergers & acquisitions are the key strategies adopted by the leading players.
Prominent players in the global market are AstraZeneca, Aurobindo Pharma, Bayer AG, Bristol-Myers Squibb Company, Cipla Ltd, F. Hoffmann-La Roche Ltd, Fresenius Kabi AG, GSK plc, Hikma Pharmaceuticals PLC, Mylan, Novartis Pharmaceuticals Corporation, Pfizer, Sanofi, and Teva Pharmaceutical Industries Ltd.
Key players have been profiled in the diuretic drugs market report based on parameters such as company overview, recent developments, product portfolio, financial overview, business segments, and business strategies.
|
Attribute |
Detail |
|
Market Size Value in 2022 |
US$ 98.8 Mn |
|
Market Forecast Value in 2031 |
US$ 157.2 Mn |
|
Growth Rate (CAGR) |
5.5% |
|
Forecast Period |
2023–2031 |
|
Historical Data Available for |
2017–2021 |
|
Quantitative Units |
US$ Mn for Value |
|
Market Analysis |
It includes segment analysis at global as well as regional level. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
|
Competition Landscape |
|
|
Format |
Electronic (PDF) + Excel |
|
Market Segmentation |
|
|
Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
It was valued at US$ 98.8 Mn in 2022
It is projected to reach more than US$ 157.2 Mn by 2031
The CAGR is anticipated to be 5.5% from 2023 to 2031
Surge in prevalence of chronic diseases and rise in awareness about benefits of diuretic drugs
North America is expected to account for major share during the forecast period
AstraZeneca, Aurobindo Pharma, Bayer AG, Bristol-Myers Squibb Company, Cipla Ltd, F. Hoffmann-La Roche Ltd, Fresenius Kabi AG, GSK plc, Hikma Pharmaceuticals PLC, Mylan, Novartis Pharmaceuticals Corporation, Pfizer, Sanofi, Teva Pharmaceutical Industries Ltd.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Diuretic Drugs Market
4. Market Overview
4.1. Introduction
4.1.1. Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Diuretic Drugs Market Analysis and Forecast, 2017-2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Key Mergers & Acquisitions
5.2. COVID-19 Pandemic Impact on Industry (Value Chain and Short / Mid / Long Term Impact)
5.3. Regulatory Scenario by Region/globally
5.4. Disease Prevalence & Incidence Rate Globally with Key Countries
5.5. Pipeline Analysis
6. Global Diuretic Drugs Market Analysis and Forecast, By Drug Class
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast By Drug Class, 2017-2031
6.3.1. Carbonic Anhydrase Inhibitors
6.3.2. Loop Diuretics
6.3.3. Miscellaneous Diuretics
6.3.4. Potassium-sparing Diuretics
6.3.5. Thiazide Diuretics
6.4. Market Attractiveness By Drug Class
7. Global Diuretic Drugs Market Analysis and Forecast, By Route of Administration
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast By Route of Administration, 2017-2031
7.3.1. Oral
7.3.2. Parenteral
7.4. Market Attractiveness By Route of Administration
8. Global Diuretic Drugs Market Analysis and Forecast, By Indication
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast By Indication, 2017-2031
8.3.1. Hypertension
8.3.2. Heart Failure
8.3.3. Kidney Stone
8.3.4. Edema
8.3.5. Others
8.4. Market Attractiveness By Indication
9. Global Diuretic Drugs Market Analysis and Forecast, By Distribution Channel
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast By Distribution Channel, 2017-2031
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies
9.3.3. Online Pharmacies
9.4. Market Attractiveness By Distribution Channel
10. Global Diuretic Drugs Market Analysis and Forecast, By Region
10.1. Key Findings
10.2. Market Value Forecast By Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness By Country/Region
11. North America Diuretic Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast By Drug Class, 2017-2031
11.2.1. Carbonic Anhydrase Inhibitors
11.2.2. Loop Diuretics
11.2.3. Miscellaneous Diuretics
11.2.4. Potassium-sparing Diuretics
11.2.5. Thiazide Diuretics
11.3. Market Value Forecast By Route of Administration, 2017-2031
11.3.1. Oral
11.3.2. Parenteral
11.4. Market Value Forecast By Indication, 2017-2031
11.4.1. Hypertension
11.4.2. Heart Failure
11.4.3. Kidney Stone
11.4.4. Edema
11.4.5. Others
11.5. Market Value Forecast By Distribution Channel, 2017-2031
11.5.1. Hospital Pharmacies
11.5.2. Retail Pharmacies
11.5.3. Online Pharmacies
11.6. Market Value Forecast By Country, 2017-2031
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Drug Class
11.7.2. By Route of Administration
11.7.3. By Indication
11.7.4. By Distribution Channel
11.7.5. By Country
12. Europe Diuretic Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast By Drug Class, 2017-2031
12.2.1. Carbonic Anhydrase Inhibitors
12.2.2. Loop Diuretics
12.2.3. Miscellaneous Diuretics
12.2.4. Potassium-sparing Diuretics
12.2.5. Thiazide Diuretics
12.3. Market Value Forecast By Route of Administration, 2017-2031
12.3.1. Oral
12.3.2. Parenteral
12.4. Market Value Forecast By Indication, 2017-2031
12.4.1. Hypertension
12.4.2. Heart Failure
12.4.3. Kidney Stone
12.4.4. Edema
12.4.5. Others
12.5. Market Value Forecast By Distribution Channel, 2017-2031
12.5.1. Hospital Pharmacies
12.5.2. Retail Pharmacies
12.5.3. Online Pharmacies
12.6. Market Value Forecast By Country/Sub-region, 2017-2031
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Italy
12.6.5. Spain
12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
12.7.1. By Drug Class
12.7.2. By Route of Administration
12.7.3. By Indication
12.7.4. By Distribution Channel
12.7.5. By Country/Sub-region
13. Asia Pacific Diuretic Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast By Drug Class, 2017-2031
13.2.1. Carbonic Anhydrase Inhibitors
13.2.2. Loop Diuretics
13.2.3. Miscellaneous Diuretics
13.2.4. Potassium-sparing Diuretics
13.2.5. Thiazide Diuretics
13.3. Market Value Forecast By Route of Administration, 2017-2031
13.3.1. Oral
13.3.2. Parenteral
13.4. Market Value Forecast By Indication, 2017-2031
13.4.1. Hypertension
13.4.2. Heart Failure
13.4.3. Kidney Stone
13.4.4. Edema
13.4.5. Others
13.5. Market Value Forecast By Distribution Channel, 2017-2031
13.5.1. Hospital Pharmacies
13.5.2. Retail Pharmacies
13.5.3. Online Pharmacies
13.6. Market Value Forecast By Country/Sub-region, 2017-2031
13.6.1. Japan
13.6.2. China
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
13.7.1. By Drug Class
13.7.2. By Route of Administration
13.7.3. By Indication
13.7.4. By Distribution Channel
13.7.5. By Country/Sub-region
14. Latin America Diuretic Drugs Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast By Drug Class, 2017-2031
14.2.1. Carbonic Anhydrase Inhibitors
14.2.2. Loop Diuretics
14.2.3. Miscellaneous Diuretics
14.2.4. Potassium-sparing Diuretics
14.2.5. Thiazide Diuretics
14.3. Market Value Forecast By Route of Administration, 2017-2031
14.3.1. Oral
14.3.2. Parenteral
14.4. Market Value Forecast By Indication, 2017-2031
14.4.1. Hypertension
14.4.2. Heart Failure
14.4.3. Kidney Stone
14.4.4. Edema
14.4.5. Others
14.5. Market Value Forecast By Distribution Channel, 2017-2031
14.5.1. Hospital Pharmacies
14.5.2. Retail Pharmacies
14.5.3. Online Pharmacies
14.6. Market Value Forecast By Country/Sub-region, 2017-2031
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
14.7.1. By Drug Class
14.7.2. By Route of Administration
14.7.3. By Indication
14.7.4. By Distribution Channel
14.7.5. By Country/Sub-region
15. Middle East & Africa Diuretic Drugs Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast By Drug Class, 2017-2031
15.2.1. Carbonic Anhydrase Inhibitors
15.2.2. Loop Diuretics
15.2.3. Miscellaneous Diuretics
15.2.4. Potassium-sparing Diuretics
15.2.5. Thiazide Diuretics
15.3. Market Value Forecast By Route of Administration, 2017-2031
15.3.1. Oral
15.3.2. Parenteral
15.4. Market Value Forecast By Indication, 2017-2031
15.4.1. Hypertension
15.4.2. Heart Failure
15.4.3. Kidney Stone
15.4.4. Edema
15.4.5. Others
15.5. Market Value Forecast By Distribution Channel, 2017-2031
15.5.1. Hospital Pharmacies
15.5.2. Retail Pharmacies
15.5.3. Online Pharmacies
15.6. Market Value Forecast By Country/Sub-region, 2017-2031
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
15.7.1. By Drug Class
15.7.2. By Route of Administration
15.7.3. By Indication
15.7.4. By Distribution Channel
15.7.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player – Competition Matrix (By Tier and Size of companies)
16.2. Market Share/Ranking Analysis By Company (2022)
16.3. Company Profiles
16.3.1. AstraZeneca
16.3.1.1. Company Overview
16.3.1.2. Drug Class Portfolio
16.3.1.3. SWOT Analysis
16.3.1.4. Strategic Overview
16.3.2. Aurobindo Pharma
16.3.2.1. Company Overview
16.3.2.2. Drug Class Portfolio
16.3.2.3. SWOT Analysis
16.3.2.4. Strategic Overview
16.3.3. Bayer AG
16.3.3.1. Company Overview
16.3.3.2. Drug Class Portfolio
16.3.3.3. SWOT Analysis
16.3.3.4. Strategic Overview
16.3.4. Bristol-Myers Squibb Company
16.3.4.1. Company Overview
16.3.4.2. Drug Class Portfolio
16.3.4.3. SWOT Analysis
16.3.4.4. Strategic Overview
16.3.5. Cipla Ltd
16.3.5.1. Company Overview
16.3.5.2. Drug Class Portfolio
16.3.5.3. SWOT Analysis
16.3.5.4. Strategic Overview
16.3.6. F. Hoffmann-La Roche Ltd
16.3.6.1. Company Overview
16.3.6.2. Drug Class Portfolio
16.3.6.3. SWOT Analysis
16.3.6.4. Strategic Overview
16.3.7. Fresenius Kabi AG
16.3.7.1. Company Overview
16.3.7.2. Drug Class Portfolio
16.3.7.3. SWOT Analysis
16.3.7.4. Strategic Overview
16.3.8. GSK plc
16.3.8.1. Company Overview
16.3.8.2. Drug Class Portfolio
16.3.8.3. SWOT Analysis
16.3.8.4. Strategic Overview
16.3.9. Hikma Pharmaceuticals PLC
16.3.9.1. Company Overview
16.3.9.2. Drug Class Portfolio
16.3.9.3. SWOT Analysis
16.3.9.4. Strategic Overview
16.3.10. Mylan
16.3.10.1. Company Overview
16.3.10.2. Drug Class Portfolio
16.3.10.3. SWOT Analysis
16.3.10.4. Strategic Overview
16.3.11. Novartis Pharmaceuticals Corporation
16.3.11.1. Company Overview
16.3.11.2. Drug Class Portfolio
16.3.11.3. SWOT Analysis
16.3.11.4. Strategic Overview
16.3.12. Pfizer
16.3.12.1. Company Overview
16.3.12.2. Drug Class Portfolio
16.3.12.3. SWOT Analysis
16.3.12.4. Strategic Overview
16.3.13. Sanofi
16.3.13.1. Company Overview
16.3.13.2. Drug Class Portfolio
16.3.13.3. SWOT Analysis
16.3.13.4. Strategic Overview
16.3.14. Teva Pharmaceutical Industries Ltd
16.3.14.1. Company Overview
16.3.14.2. Drug Class Portfolio
16.3.14.3. SWOT Analysis
16.3.14.4. Strategic Overview
List of Tables
Table 01: Global Diuretic Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031
Table 02: Diuretic Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017‒2031
Table 03: Diuretic Drugs Market Value (US$ Mn) Forecast, by Indication, 2017‒2031
Table 04: Global Diuretic Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 05: Global Diuretic Drugs Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 06: North America Diuretic Drugs Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 07: North America Diuretic Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031
Table 08: North America Diuretic Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017‒2031
Table 09: North America Diuretic Drugs Market Value (US$ Mn) Forecast, by Indication, 2017‒2031
Table 10: North America Diuretic Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 11: Europe Diuretic Drugs Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017–2031
Table 12: Europe Diuretic Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031
Table 13: Europe Diuretic Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017‒2031
Table 14: Europe Diuretic Drugs Market Value (US$ Mn) Forecast, by Indication, 2017‒2031
Table 15: Europe Diuretic Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 16: Asia Pacific Diuretic Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 17: Asia Pacific Diuretic Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031
Table 18: Asia Pacific Diuretic Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017‒2031
Table 19: Asia Pacific Diuretic Drugs Market Value (US$ Mn) Forecast, by Indication, 2017‒2031
Table 20: Asia Pacific Diuretic Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 21: Latin America Diuretic Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 22: Latin America Diuretic Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031
Table 23: Latin America Diuretic Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017‒2031
Table 24: Latin America Diuretic Drugs Market Value (US$ Mn) Forecast, by Indication, 2017‒2031
Table 25: Latin America Diuretic Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 26: Middle East & Africa Diuretic Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 27: Middle East & Africa Diuretic Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031
Table 28: Middle East & Africa Diuretic Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017‒2031
Table 29: Middle East & Africa Diuretic Drugs Market Value (US$ Mn) Forecast, by Indication, 2017‒2031
Table 30: Middle East & Africa Diuretic Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
List of Figures
Figure 01: Global Diuretic Drugs Market Value (US$ Mn) Forecast, 2017–2031
Figure 02: Global Diuretic Drugs Market Value Share, by Drug Class, 2022
Figure 03: Global Diuretic Drugs Market Value Share, by Route of Administration, 2022
Figure 04: Global Diuretic Drugs Market Value Share, by Indication, 2022
Figure 05: Global Diuretic Drugs Market Value Share, by Distribution Channel, 2022
Figure 06 Global Diuretic Drugs Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 07: Global Diuretic Drugs Market Attractiveness Analysis, by Drug Class, 2023-2031
Figure 08: Global Diuretic Drugs Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 09: Global Diuretic Drugs Market Attractiveness Analysis, by Route of Administration, 2023-2031
Figure 10: Global Diuretic Drugs Market Value Share Analysis, by Indication, 2022 and 2031
Figure 11: Global Diuretic Drugs Market Attractiveness Analysis, by Indication, 2023-2031
Figure 12: Global Diuretic Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 13: Global Diuretic Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 14: Global Diuretic Drugs Market Value Share Analysis, by Region, 2022 and 2031
Figure 15: Global Diuretic Drugs Market Attractiveness Analysis, by Region, 2023-2031
Figure 16: North America Diuretic Drugs Market Value (US$ Mn) Forecast, 2017–2031
Figure 17: North America Diuretic Drugs Market Value Share Analysis, by Country, 2022 and 2031
Figure 18: North America Diuretic Drugs Market Attractiveness Analysis, by Country, 2023-2031
Figure 19: North America Diuretic Drugs Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 20: North America Diuretic Drugs Market Attractiveness Analysis, by Drug Class, 2023-2031
Figure 21: North America Diuretic Drugs Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 22: North America Diuretic Drugs Market Attractiveness Analysis, by Route of Administration, 2023-2031
Figure 23: North America Diuretic Drugs Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 24: North America Diuretic Drugs Market Attractiveness Analysis, by Indication, 2023-2031
Figure 25: North America Diuretic Drugs Market Value Share Analysis, by Indication, 2022 and 2031
Figure 26: North America Diuretic Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 27: Europe Diuretic Drugs Market Value (US$ Mn) Forecast, 2017–2031
Figure 28: Europe Diuretic Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 29: Europe Diuretic Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 30: Europe Diuretic Drugs Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 31: Europe Diuretic Drugs Market Attractiveness Analysis, by Drug Class, 2023-2031
Figure 32: Europe Diuretic Drugs Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 33: Europe Diuretic Drugs Market Attractiveness Analysis, by Route of Administration, 2023-2031
Figure 34: Europe Diuretic Drugs Market Value Share Analysis, by Indication, 2022 and 2031
Figure 35: Europe Diuretic Drugs Market Attractiveness Analysis, by Indication, 2023-2031
Figure 36: Europe Diuretic Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 37: Europe Diuretic Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 38: Asia Pacific Diuretic Drugs Market Value (US$ Mn) Forecast, 2017–2031
Figure 39: Asia Pacific Diuretic Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 40: Asia Pacific Diuretic Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 41: Asia Pacific Diuretic Drugs Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 42: Asia Pacific Diuretic Drugs Market Attractiveness Analysis, by Drug Class, 2023-2031
Figure 43: Asia Pacific Diuretic Drugs Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 44: Asia Pacific Diuretic Drugs Market Attractiveness Analysis, by Route of Administration, 2023-2031
Figure 45: Asia Pacific Diuretic Drugs Market Value Share Analysis, by Indication, 2022 and 2031
Figure 46: Asia Pacific Diuretic Drugs Market Attractiveness Analysis, by Indication, 2023-2031
Figure 47: Asia Pacific Diuretic Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 48: Asia Pacific Diuretic Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 49: Latin America Diuretic Drugs Market Value (US$ Mn) Forecast, 2017–2031
Figure 50: Latin America Diuretic Drugs Market Value Share Analysis, by Country/Sub-Region, 2022 and 2031
Figure 51: Latin America Diuretic Drugs Market Attractiveness Analysis, by Country/Sub-Region, 2022-2031
Figure 52: Latin America Diuretic Drugs Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 53: Latin America Diuretic Drugs Market Attractiveness Analysis, by Drug Class, 2023-2031
Figure 54: Latin America Diuretic Drugs Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 55: Latin America Diuretic Drugs Market Attractiveness Analysis, by Route of Administration, 2023-2031
Figure 56: Latin America Diuretic Drugs Market Value Share Analysis, by Indication, 2022 and 2031
Figure 57: Latin America Diuretic Drugs Market Attractiveness Analysis, by Indication, 2023-2031
Figure 58: Latin America Diuretic Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 59: Latin America Diuretic Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 60: Middle East & Africa Diuretic Drugs Market Value (US$ Mn) Forecast, 2017–2031
Figure 61: Middle East & Africa Diuretic Drugs Market Value Share Analysis, by Country/Sub-Region, 2022 and 2031
Figure 62: Middle East & Africa Diuretic Drugs Market Attractiveness Analysis, by Country/Sub-Region, 2022-2031
Figure 63: Middle East & Africa Diuretic Drugs Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 64: Middle East & Africa Diuretic Drugs Market Attractiveness Analysis, by Drug Class, 2023-2031
Figure 65: Middle East & Africa Diuretic Drugs Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 66: Middle East & Africa Diuretic Drugs Market Attractiveness Analysis, by Route of Administration, 2023-2031
Figure 67: Middle East & Africa Diuretic Drugs Market Value Share Analysis, by Indication, 2022 and 2031
Figure 68: Middle East & Africa Diuretic Drugs Market Attractiveness Analysis, by Indication, 2023-2031
Figure 69: Middle East & Africa Diuretic Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 70: Middle East & Africa Diuretic Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 71: Company Share Analysis, 2022
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Diuretic Drugs Market
